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Introduction
The fatty acid ethanolamides (FAEs) constitute a newly characterized family of lipid mediators, 1 which include the endogenous cannabinoid (endocannabinoid) anandamide 2 (arachidonoylethanolamide, 1, Figure 1 ), the intestinal satiety factor oleoylethanolamide 3 (OEA, 2, Figure 1 ), and the peripheral analgesic and antiinflammatory factor palmitoylethanolamide 4 (PEA, 3, Figure 1 ). The FAEs are normally present in mammalian organs and tissues, where their formation is thought to be mediated through receptor-dependent cleavage of N-acylphosphatidylethanolamine (NAPE), a minor phospholipid component of cell membranes. 5 After formation and release from cells, polyunsaturated FAEs such as anandamide may be eliminated via a twostep process consisting of high-affinity transport into cells, 6 followed by intracellular degradation catalyzed by the serine hydrolase, fatty acid amide hydrolase (FAAH). 7 On the other hand, saturated and monounsaturated FAEs such as OEA and PEA are not substrates for transmembrane transport and their inactivation may be exclusively mediated via FAAH-catalyzed hydrolysis. 6a,8 Various classes of FAAH inhibitors have been identified. Reversible inhibitors include endogenous compounds such as 2-octyl-γ-bromoacetoacetate 9 (4, Figure  2 ) as well as numerous synthetic agents containing electrophilic carbonyls, such as trifluoromethyl ketones, R-keto esters, and R-keto amides. 10 Particularly promising within this group are the remarkably potent acyl heterocycles developed by Boger and collaborators, 11 among which 1-oxazolo[4, 5-b] pyridin-2-yl ketones substituted with a C8-C12 unsaturated chain or with a phenylalkyl chain of four to eight methylene units (e.g., compound 5, Figure 2 ) gave the best results. Irreversible inhibitors comprise fatty acid sulfonyl fluorides or fluorophosphonates such as hexadecanesulfonyl fluoride 12 (AM374, 6, Figure 2 ).
Although the pharmacological properties of anandamide and other FAEs underscore the potential therapeutic interest of FAAH inhibition, 5b,13 the development of suitable clinical candidates from currently available inhibitors may be difficult. The presence of a lipid-like chain may confer to these compounds a number of unfavorable biopharmaceutical properties, including low water solubility, high plasma protein binding, and high accumulation in fat tissues. Furthermore, the alkyl chain also may limit the target selectivity of current FAAH inhibitors by increasing their tendency to bind to other endocannabinoid-metabolizing enzymes, such as monoglyceride lipase 14 and cannabinoid receptors. 12a,b,15 Therefore, the design of potent and selective small-molecule inhibitors of FAAH remains an essential step in the validation of this enzyme as a therapeutic target.
The cloning of rodent and human FAAH has revealed the existence of a close structural relationship among different mammalian forms of this enzyme and between these and bacterial amidases. This homology is particularly evident at the level of the amidase "signature sequence", a highly conserved domain enriched in glycine and serine residues. 7, 16 Site-directed mutagenesis studies have shown that three serine residues within this domain are essential for catalytic activity (S217, S218, and S241), one of which (S241) may act as nucleophile during the catalytic process. This nucleophilic serine may be activated by the lysine residue K142 rather than through the Ser-His-Asp interaction characteristic of other serine hydrolases. 17 In the present study, we report on the synthesis of a series of alkylcarbamic acid aryl esters (9) , designed as inhibitors of FAAH by progressive modification of the structure of a known inhibitor of the serine hydrolase acetylcholinesterase (AChE) (compound 19), and on the biological activity of some other known carbamates (compounds 7 and 20-27 in Table 1 ). We investigated the importance for FAAH inhibition of the carbamate group and the stereoelectronic properties of its N-and the O-substituents. In particular, we evaluated the role of the carbamate group by replacing it with isoster groups. Moreover, carbamic acid esters having confor- We have recently shown that representative members of this series (e.g., URB532, 7, Figure 3 ) are systemically active inhibitors of FAAH activity. 18 The fact that these compounds exert profound anxiolytic-like effects in rats suggests that they may provide candidates for the development of innovative antianxiety medicines. 18 
Chemistry
The synthesis of compounds 9, 11, 13, 16, and 18 is illustrated in Scheme 1. Cyclohexylcarbamic acid aryl esters 9a-i were obtained by addition of the suitable aryl alcohols to isocyanatocyclohexane. Carbamate 11 was prepared by treatment of diimidazol-1-ylmethanone (10) with biphenyl-3-ylamine, 19 followed by cyclohexanol, and amide 13 from naphthalene-2-carboxylic acid (12) via acyl chloride. The preparation of 16a-d involved coupling of an iso(thio)cyanate with an appropriate thiol or amine. Finally, the thiocarbamate 18 was synthesized from thiophosgene (17), naphthalen-2-ol, and cyclohexylamine.
Compounds 7 and 19-27 were purchased from SigmaAldrich.
Results and Discussion
We measured FAAH activity in rat brain membranes, using [ 3 H]anandamide as a substrate. 18 Half-maximal concentrations (IC 50 ) for inhibition of FAAH activity by compounds 9a-i, 11, 13, 16a-d, and 19-27 are reported in Table 1 . We first tested the AChE inhibitor carbaryl (19) and its p-tolyl (20) and 2-naphthyl (21) analogues. Only the latter analogue showed a weak inhibitory activity, which was enhanced by introducing more lipophilic alkyl residues on the carbamic nitrogen. Thus, replacing the methyl group of 21 with a cyclohexyl resulted in a 60-fold decrease in IC 50 (compound 22). Submicromolar potencies also were observed with the n-butyl derivatives 7 and 23, whereas the very low activity of 24 confirmed the essential role of the Osubstituent in FAAH inhibition. Importantly, unlike carbaryl (19) , which inhibited eel acetylcholinesterase (AchE) activity with an IC 50 of 3.1 µM, compounds 7 and 20-24 had no effect on the activities of this enzyme or of horse-serum butyrylcholinesterase when tested at concentrations as high as 30 µM (data not shown). Furthermore, the compounds (1-100 µM) did not displace the binding of [ 3 H]WIN-55212-2 (10 nM) to rat cerebellar CB 1 receptors or human recombinant CB 2 receptors and did not affect [ 3 H]anandamide (100 nM) transport in astrocytoma cells (data not shown).
Next, to examine the role of the carbamate function in FAAH inhibition, we prepared several isosters of 22. Both the ester 13 and the urea 16a were ineffective. Furthermore, replacement of oxygen with sulfur (compounds 16b-d, 18) also led to inactive analogues, with the partial exception of the thiocarbamic acid S-naphthyl ester 16b. These results suggest that the carbamic group is essential for inhibition of FAAH activity by this series of compounds.
The hypothesis that guided our subsequent design was that the FAAH inhibitory activity may be improved by introducing aromatic substituents of defined shape on the oxygen atom. We further assumed that this moiety acted as a leaving group after the nucleophilic attack of the S241 residue of FAAH on the carbonyl of the inhibitors, resulting in enzyme carbamoylation. Though direct evidence for this mechanism is still needed, the findings that compound 7 inhibits FAAH activity in a noncompetitive manner (Figure 4 ) and that extensive dialysis (1 L/mL of sample, 16 h at 4°C) does not reverse inhibition (data not shown) support the notion that these compounds interact irreversibly with FAAH.
Comparison of the structures of compounds 7 and 22 provided a first insight into the shape requirements for the O-substituent. A systematic conformational analysis of the benzyloxyphenyl fragment of 7 revealed two families of accessible conformers, mainly differing in the torsion angle around the O-CH 2 bond, with the two phenyl rings in anti or in gauche conformation. Apparently, the gauche conformation of 7 more closely resembled the shape of the naphthyl derivative 23 when the compounds were superimposed via their common carbamate group ( Figure 5A ). This led us to hypothesize that a bent shape of the carbamate O-substituent could favor enzyme inhibition, possibly by allowing a greater steric complementarity between the inhibitor and the active site of the enzyme. This hypothesis was further developed by supposing that the aryloxy group may mimic the fatty acid chain of anandamide and other FAEs (e.g., 1-3) by counterfeiting the arrangement of the first 10-12 carbon atoms in the so-called "U-shaped" conformation of these molecules. 20 Accordingly, we conducted a systematic exploration of the steric requirements of the aromatic O-substituents by synthesizing a series of carbamates in which the shape of the O-residue was gradually modified, while maintaining the cyclohexyl substituent on the carbamic nitrogen. Starting from the phenyl and naphthyl derivatives 9a and 22, we prepared a series of compounds with lipophilic groups potentially able to occupy either a region of space antipodal to the carbamate group (9e, 25, 26) or a region corresponding to the meta position of the phenyl ring (9a-d,f,g). The design of these compounds took into consideration the possibility of calculating a 3D-QSAR model correlating steric parameters with inhibitory potency after superposition of their modeled structures.
Within this second set of compounds, greater inhibitory potencies were obtained with those molecules that had a bent shape. In particular, we observed the strongest FAAH inhibition with the m-biphenyl derivative URB524 (9g), whose IC 50 value (63 nM) indicates a 36-fold increase in potency over the isomeric pbiphenyl derivative 26. The comparison between 9e and 9f, 9c and 9d, and 9b and 25 is also suggestive of a similar trend. While the O-phenyl derivative 9a was almost inactive, we obtained compounds of moderate to good inhibitory potency by substituting the meta position of 9a with groups of suitable sizes (9b,h,g). Importantly, the carbamates 9a-g, 25, and 26 did not significantly interact with AChE or with cannabinoidrelated targets such as CB 1 or CB 2 cannabinoid receptors and endocannabinoid transporter at concentrations as high as 30 µM.
It is noteworthy that the m-biphenyl fragment of 9g may be superposed to the first 10 carbons of the fatty acid chain of arachidonic acid in the conformations adopted by this compound when bound to various proteins. The coordinates of such complexes are available through the Protein Data Bank. 21 Figure 6 shows the superposition of 9g on arachidonic acid in the conformation the latter adopts when interacting with human adipocyte lipid-binding protein, 22 COX-1, 23 and COX-2. 24 It should be noted that the two phenyl rings of 9g can occupy regions of space corresponding to the first two cis double bonds of arachidonic acid. A folded conformation similar to that illustrated in Figure 5B was found, together with other more straight conformations, for arachidonic acid in complex with human serum albumin. 25 Similar folded conformations also were observed for oleic acid and other unsaturated fatty acids bound to human fatty acid binding proteins (FABP). 26 These observations led us to consider the m-biphenyl fragment as a putative bioisoster of the first moiety of such chains, being able to reproduce the bent shape of the first two cis-double bonds of the arachidonyl chain. We next replaced the aromatic O-substituent with flexible alkyl chains. In the 2-acyloxazolopyridine series of competitive FAAH inhibitors described by Boger and collaborators, 11 the introduction of an ω-phenylpentyl group leads to one of the most potent inhibitors. By contrast, in our series the presence of the same moiety was detrimental to the inhibitory activity (see compounds 27 and 9i). Together with their differences in inhibition kinetics, these results support the notion that the two classes of compounds inhibit FAAH through separate mechanisms.
A further indication of the distinct SAR profile of the N-alkylcarbamic acid aromatic esters described here is the fact that compound 11, which has a bent shape like 9g but inverted N-and O-substituents, was inactive. This suggests that the binding pockets of the two moieties have specific stereoelectronic requirements.
The correlation between molecular shape and FAAH inhibitor potency was tested by 3D-QSAR methods. A number of key compounds characterized by variations of their steric (and not electrostatic or lipophilic) features were selected, and only the correlation between steric field and biological activity was investigated. A 3D-QSAR analysis was performed by partial least squares (PLS) regression on the comparative molecular similarity index analysis (CoMSIA) steric field 27 employing, as the dependent variable, the inhibitory potency expressed on a -log scale (pIC 50 ). Only the carbamate derivatives having a lipophilic N-substituent and an aromatic O-substituent were included in the analysis, since they represented a chemically homogeneous set with an initial standard deviation in pIC 50 values of 0.67 units around a mean value of 6.06.
The superposition of the carbamate fragments and the phenyl rings (see Experimental Section) led to a PLS model with two latent variables endowed with appreciable descriptive and predictive power (r 2 ) 0.82, s ) 0.32, q 2 LOO ) 0.54) for the 14-compound set, whose experimental and calculated pIC 50 values are reported in Table 2 and graphically plotted in Figure 6A .
The coefficients of the steric field are represented in Figure 8 as isopotential surfaces. As can be observed from the green and blue surfaces corresponding to a positive and very positive correlation, respectively, between steric occupancy and potency, two favorable regions were detected by our model. The first (at the top right of Figure 6B ) was due to the lower mean pIC 50 values observed for the N-butyl derivatives with respect to the N-cyclohexyl ones. It should be noted that this positive region would be much more relevant if the compounds having small N-substituents (19-21) could be included in the analysis, but this was precluded by the fact that only one of them had a measurable IC 50 . As a consequence, the importance of the N-substituent is underestimated by our 3D-QSAR model, which, however, was developed essentially to investigate the O-substituent requirements. Indeed, a larger and deeper favorable region was observed for this moiety, as illustrated by the green and blue volumes at the bottom of Figure 6B , indicating the presence of steric bulk, positively correlated with inhibitory potency, around the meta position of the proximal ring of the O-biphenyl substituent. This region corresponds to the second ring of the naphthyl system (especially the areas about its 7 and 8 positions) and of the distal phenyl of the styryl substituent in its (Z)-configuration. It is reasonable to assume the proximity of this region to the binding site surface of FAAH, which would result in an improvement of dispersion forces and/or lipophilic interaction between the enzyme and the inhibitor. Thus, the O-aromatic moiety, which is hypothesized to serve as a leaving group in the reaction leading to enzyme carbamoylation, would exert its effect on inhibitory potency at an early recognition stage of the process. We observed a small region with moderately negative coefficients, represented by the yellow surface at the bottom left of Figure 6B , opposite the point of attachment of the phenyl ring to the carbamate group. It indicates that longer straight fragments can be accommodated at the binding pocket in a less efficient manner than the folded ones. The most relevant example is represented by p-biphenyl derivative 26, whose potency is much lower than that of its m-biphenyl isomer 9g.
We interpret the CoMSIA coefficients to indicate the existence of a large cavity with a curved shape in the active site of enzyme, where suitable O-substituents can be accommodated, so that the interaction of their carbonyl group with the active serine of the enzyme is facilitated. This result further highlights the similarity between the m-biphenyl moiety and the conformation of arachidonic acid bound to FABP (Figure 6 ), strengthening the initial hypothesis that FAEs bind to FAAH in a folded conformation, at least for the first 10 carbon atoms. We cannot exclude, however, that the fatty acyl chain of anandamide and the O-substituent of our carbamate esters are docked to different binding pockets within the FAAH active site. The availability of FAAH 3D coordinates, which were published for a covalent adduct of the enzyme with O-methylarachidonyl fluorophosphonate (MAFP) 28 while the present manuscript was under review, may help to resolve this issue. It is worth noting that in this crystal the arachidonyl chain of the inhibitor takes a turn after its first double bond and is flanked by aromatic residues interacting with the first two double bonds, which may be mimicked by the two phenyl rings in compound 9g.
In conclusion, we have characterized a new class of FAAH inhibitors, namely, alkylcarbamic acid aryl esters, and demonstrated that their inhibitory potency can be improved by shape modulation of the aromatic O-substituent. The marked anxiolytic-like properties of these compounds 18 should encourage further investigations of their SAR. Indeed, a systematic structural modulation of the biphenyl derivative 9g is currently underway in our laboratories.
Experimental Section
(a) Chemicals, Materials, and Methods. All reagents and compounds 7 and 19-27 were purchased from Sigma-Aldrich with the exception of 8c, 29 8d, 30 8e, 31 8h, 32 and biphenyl-3-ylamine, 19 whose preparation is reported in the literature. Solvents were RP grade unless otherwise indicated. Purification of the crude materials obtained from the reactions, affording the desired products, was carried out by flash column chromatography on silica gel (Kieselgel 60, 0.040-0.063 mm, Merck). TLC analyses were performed on precoated silica gel on aluminum sheets (Kieselgel 60 F 254, Merck). Melting points were determined on a Bü chi SMP-510 capillary melting point apparatus and are uncorrected. The structure of the unknown compounds was unambiguously assessed by MS, 1 H NMR, IR, and elemental analysis. EI-MS spectra (70 eV) were recorded with a Fisons Trio 1000 spectrometer. Only molecular ions (M + ) and base peaks are given. ). Elemental analyses were performed on a Carlo Erba analyzer. All products had satisfactory (within (0.4 of theoretical values) C, H, N analyses results. (9a-e,g-i) . To a stirred mixture of the suitable aryl alcohol 8a-e,g-i (0.5 mmol) in toluene (3 mL), Et3N (3 mg, 0.004 mL, 0.03 mmol) and c-C6H11NCO (69 mg, 0.07 mL, 0.55 mmol) were added. After refluxing the reactants for 5 h, a further amount of c-C 6H11NCO (34 mg, 0.035 mL, 0.27 mmol) was added, and the mixture again reacted for 3 h [9g, 19 h; in the case of 9a,b a third addition of c-C 6H11NCO (34 mg, 0.035 mL, 0.27 mmol) was necessary; overall, these reactions required 24 h; in the case of 9e, the initial mixture was refluxed 8 h, no further addition of c-C6H11-NCO being necessary], then cooled, and concentrated. Purification of the residue by column cromatography (cyclohexane/ EtOAc 9:1 for 9a,b,h; 8:2 for 9i; 85:15 for 9c; 95:5 for 9g; CH2Cl2 for 9d,e) and recrystallization gave 9a-e,g-i.
General Procedure for the Synthesis of Cyclohexylcarbamic Acid Aryl Esters
Cyclohexylcarbamic Acid Phenyl Ester (9a). White needles. Yield: 73% (80 mg). Mp: 137°C (MeOH) (lit. 128-30°C from 50% EtOH). 33 34 mixture of Zand E-stilben-4-ols (0.456 g, 2.33 mmol). This was dissolved in toluene (13 mL), and Et3N (0.014 g, 0.019 mL, 0.14 mmol) and c-C6H11NCO (0.32 g, 0.33 mL, 2.57 mmol) were added. The mixture was refluxed under stirring for 3 h, cooled, and concentrated. Purification of the residue by column cromatography (cyclohexane/EtOAc 85:15) gave the desired product along with a substantial amount of 9e. Synthesis of 1-Cyclohexyl-3-naphthalen-2-ylurea (16a). 35 A stirred mixture of naphthalen-2-ylamine (15a) (143 mg, 1 mmol), c-C6H11NCO (14a) (138 mg, 0.14 mL, 1.1 mmol), Et3N (5 mg, 0.07 mL, 0.05 mmol), and toluene (5 mL) was refluxed for 20 h. Two further amounts of 14a (69 mg, 0.07 mL, 0.55 mmol) were added during this period, after 5 and 3 h, respectively. The mixture was then cooled and concentrated. Purification of the residue by column chromatography (cyclohexane/EtOAc 85:15) and recrystallization gave 16a as a white solid. Yield: 30% (80 mg). Mp: 204°C (MeOH) (lit. 204-205°C
). 35 Anal. (C17H20N2O) C, H, N. Synthesis of Cyclohexylthiocarbamic Acid S-Naphthalen-2-yl Ester (16b). 36 To a stirred solution of t-BuOK (2.1 mg, 0.018 mmol) and naphthalene-2-thiol (15b) (300 mg, 1.875 mmol) in toluene (0.6 mL), c-C6H11NCO (14a) (235 mg, 0.24 mL, 1.875 mmol) in toluene (0.6 mL) was added dropwise at 50°C during 5 min. The mixture was stirred at the same temperature for 15 min and then cooled and filtered. Recrystallization gave 16b as a white solid. Yield: 60% (318 mg). Synthesis of 1-Cyclohexyl-3-naphthalen-2-ylthiourea (16c). To a stirred solution of naphthalen-2-ylamine (15a) (143 mg, 1 mmol) in CH2Cl2 (2 mL), c-C6H11NCS (14b) (141 mg, 0.14 mL, 1 mmol) was added. The mixture was stirred at room temperature for 5 h, refluxed for 14 h, cooled, and concentrated. Purification of the residue by column cromatography (CH 2Cl2) and recrystallization gave 16c as white solid. Yield: 51% (145 mg δ 1.02-2.18 (m, 11H), 4.31 (m, 1H), 6.02 (d, 1H) Synthesis of Cyclohexylthiocarbamic Acid O-Naphthalen-2-yl Ester (18). To a stirred solution of C(S)Cl2 (17) (57 mg, 0.038 mL, 0.5 mmol) in CHCl3 (2 mL), sodium naphthalen-2-olate [obtained as a sticky solid by adding naphthalen-2-ol (72 mg, 0.5 mmol) to a solution of Na (0.11 mg, 0.5 mmol) in dry MeOH (1 mL), stirring the mixture for 0.5 h, evaporating the solvent, and drying the residue] was added (exothermic reaction). After stirring the reactants at room temperature for 1 h, c-C 6H11NH2 (99 mg, 0.11 mL, 1 mmol) was added (exothermic reaction). The mixture reacted at room temperature for 4 h and then was concentrated. H 2O was cautiously added to the residue, and the mixture was extracted with EtOAc. The combined organic layers were dried (Na 2SO4) and concentrated. Purification of the residue by column chromatography (cyclohexane/EtOAc 9:1) and recrystallization gave 18 as a light-yellow, garlic-smelling solid. Yield: 60% (86 mg 18 Cholinesterase assays were conducted with a commercial kit (Sigma, St. Louis, MO), using purified enzymes (electric eel acetylcholinesterase type V-S and horse-serum cholinesterase, both from Sigma, St. Louis, MO) and following vendor's instructions.
(c) Molecular Modeling. Molecular models were built by applying the standard tools in Sybyl, version 6.6 (Tripos Inc., 1699 South Hanley Rd, Louis, MO, 63144). Their geometries were optimized by energy minimization, employing the Merck molecular force field 94s (MMFF94s), 38 implemented in Sybyl. Conformational analysis was performed by systematic scanning of the rotatable bonds and energy minimization to a gradient of 0.01 kcal mol -1 Å -1
. The conformations giving the highest intersection volume with the template structure were employed for compound alignment in the following analysis. For 3D-QSAR analysis, minimum energy conformations of the compounds were aligned by a rigid root-mean-square (rms) fit of the five atoms in the carbamate fragment and the six carbon atoms in the closer phenyl ring, employing 9g as a template structure. For compounds 7 and 9f, the centroid of the distal phenyl ring was also superposed to that of 9g. The CoMSIA 27 modules of Sybyl were employed for the quantitative structureactivity study. The CoMSIA steric field was calculated within a lattice with a grid resolution of 2 Å, whose extension was at least 4 Å beyond every molecular boundary in all directions. An sp 3 carbon was taken as the probe atom. Regression analyses were performed using the PLS 39 algorithm in Sybyl. The cross-validation technique with the leave-one-out (LOO) procedure 40 was applied to calculate q 2 LOO as a rough estimate of the predictive power and to choose the optimal number of latent variables. Variables with an energy standard deviation lower than 2 kcal/mol were discarded to minimize the influence of noisy columns and to speed the computation. The final noncross-validated analyses were derived with the number of latent variables corresponding to the first maximum q 2 LOO value, or before nonsignificant increase of q 2 LOO (i.e., <0.05).
No filter was applied to the dependent variables in this case. The contour volumes of the 3D-QSAR model, represented in Figure 6B , correspond to the following cutoff values for the product of the PLS coefficients and the standard deviation of the steric potential: (blue) >+0.05, (green) >+0.01, (yellow) <-0.01, (red) <-0.05.
